JP2010530431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530431A5 JP2010530431A5 JP2010513266A JP2010513266A JP2010530431A5 JP 2010530431 A5 JP2010530431 A5 JP 2010530431A5 JP 2010513266 A JP2010513266 A JP 2010513266A JP 2010513266 A JP2010513266 A JP 2010513266A JP 2010530431 A5 JP2010530431 A5 JP 2010530431A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- group
- structural formula
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 102000011990 Sirtuin Human genes 0.000 claims 4
- 108050002485 Sirtuin Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Chemical group 0.000 claims 2
- 239000001301 oxygen Chemical group 0.000 claims 2
- -1 1,2,4-triazolylmethyl group Chemical group 0.000 claims 1
- 101000654472 Homo sapiens NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 108091005770 SIRT3 Proteins 0.000 claims 1
- 102000000344 Sirtuin 1 Human genes 0.000 claims 1
- 108010041191 Sirtuin 1 Proteins 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 230000006196 deacetylation Effects 0.000 claims 1
- 238000003381 deacetylation reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 102000056482 human SIRT1 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 239000002510 pyrogen Substances 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93663307P | 2007-06-20 | 2007-06-20 | |
| US60/936,633 | 2007-06-20 | ||
| PCT/US2008/007771 WO2008156866A1 (en) | 2007-06-20 | 2008-06-20 | Sirtuin modulating imidazothiazole compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010530431A JP2010530431A (ja) | 2010-09-09 |
| JP2010530431A5 true JP2010530431A5 (cg-RX-API-DMAC10.html) | 2011-08-04 |
| JP5281081B2 JP5281081B2 (ja) | 2013-09-04 |
Family
ID=39810276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513266A Expired - Fee Related JP5281081B2 (ja) | 2007-06-20 | 2008-06-20 | サーチュイン調節性イミダゾチアゾール化合物 |
Country Status (26)
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| CA2599989A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| CA2617557A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
| WO2007041641A1 (en) * | 2005-10-03 | 2007-04-12 | University Of Tennessee Research Foundation | Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
| CL2008001821A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| US8391970B2 (en) * | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
| WO2009099643A1 (en) * | 2008-02-07 | 2009-08-13 | The J. David Gladstone Institutes | Use of sirt1 activators or inhibitors to modulate an immune response |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| US9211409B2 (en) | 2008-03-31 | 2015-12-15 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of T-cell activity |
| EP2273992B1 (en) | 2008-05-01 | 2016-05-25 | Glaxosmithkline LLC | Quinolines and related analogs as sirtuin modulators |
| CN104193740A (zh) | 2008-07-03 | 2014-12-10 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物 |
| ES2517690T3 (es) | 2008-09-29 | 2014-11-03 | Glaxosmithkline Llc | Quinazolinona, quinolona y análogos relacionados como moduladores de sirtuina |
| ES2452484T3 (es) | 2008-11-18 | 2014-04-01 | Setpoint Medical Corporation | Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria |
| BRPI0917626A2 (pt) | 2008-12-08 | 2017-07-11 | Univ Northwestern | Método para modular atividade do fator 1 de transcrição do choque térmico (hsf1) em uma célula, método para aumentar ou diminuir a atividade de hsf1 em um indivíduo necessitando do mesmo método para tratar um paciente, método para identificar um agente que modula a atividade de hsf1 em uma célula, método para ativar a resposta ao choque térmico em uma célula ou em um paciente necessitando do mesmo e composição farmacêutica |
| EP2376502B1 (en) | 2008-12-19 | 2015-06-17 | GlaxoSmithKline LLC | Thiazolopyridine sirtuin modulating compounds |
| US8996116B2 (en) * | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US20110054569A1 (en) * | 2009-09-01 | 2011-03-03 | Zitnik Ralph J | Prescription pad for treatment of inflammatory disorders |
| US8612002B2 (en) | 2009-12-23 | 2013-12-17 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| EP2440284B1 (en) | 2009-06-09 | 2018-09-12 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
| CA2779303A1 (en) | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
| EP2496594B1 (en) | 2009-11-06 | 2018-01-17 | The J. David Gladstone Institutes | Methods and compositions for modulating tau levels |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| EP2558589A4 (en) | 2010-04-15 | 2014-01-01 | Glaxosmithkline Llc | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS FOR THIS |
| KR101915115B1 (ko) * | 2010-05-03 | 2018-11-05 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료 |
| US20130171125A1 (en) * | 2010-05-11 | 2013-07-04 | National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DDS), U.S. Government | Methods for the Regulation of Cellular Metabolism Through the Modulation of SIRT3 Activity |
| US20130338178A1 (en) | 2011-02-02 | 2013-12-19 | The Trustees Of Princeton University | Sirtuin modulators as inhibitors of cytomegalovirus |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| EP2707094B1 (en) | 2011-05-09 | 2016-02-03 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| EP2731599B1 (en) | 2011-07-15 | 2018-10-31 | NuSirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AU2012352177A1 (en) | 2011-12-13 | 2014-07-10 | Buck Institute For Research On Aging | Methods for improving medical therapies |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| CN108452311A (zh) | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
| CN105228627B (zh) | 2013-03-15 | 2018-07-13 | 纽斯尔特科学公司 | 亮氨酸和烟酸降低脂质水平 |
| WO2015002892A1 (en) * | 2013-07-01 | 2015-01-08 | Meier Joshua Abraham | Methods of treating diseases by modulating mitochondrial dna deletions |
| SG11201607075TA (en) | 2014-02-27 | 2016-09-29 | Nusirt Sciences Inc | Compositions and methods for the reduction or prevention of hepatic steatosis |
| US10316054B2 (en) | 2014-06-02 | 2019-06-11 | Glaxosmithkline Intellectual Property (No. 2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
| MX2016016071A (es) | 2014-06-06 | 2017-07-11 | Glaxosmithkline Intellectual Property (No 2) Ltd | Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos. |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| KR101839688B1 (ko) | 2015-08-21 | 2018-03-19 | 중앙대학교 산학협력단 | 이미다조티아졸 유도체 또는 이의 약학적으로 허용 가능한 염 및 이의 의약적 용도 |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| WO2017123161A1 (en) * | 2016-01-15 | 2017-07-20 | Agency For Science, Technology And Research | Inhibition of intracellular growth of mycobacterium species and its applications |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| US10314501B2 (en) | 2016-01-20 | 2019-06-11 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| US10695569B2 (en) | 2016-01-20 | 2020-06-30 | Setpoint Medical Corporation | Control of vagal stimulation |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| CN109475572A (zh) | 2016-02-22 | 2019-03-15 | 宾夕法尼亚州大学信托人 | 用于增强肝再生的方法 |
| EP3668402B1 (en) | 2017-08-14 | 2024-07-31 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| CN109700790A (zh) * | 2018-12-28 | 2019-05-03 | 中南大学湘雅医院 | 一种靶向AQP3的抗皮肤衰老药物Butein |
| EP3952982B1 (en) | 2019-04-12 | 2024-03-27 | Setpoint Medical Corporation | Vagus nerve stimulation system to treat neurodegenerative disorders |
| CN111000854B (zh) * | 2019-12-30 | 2023-06-09 | 昆药集团股份有限公司 | 曲札茋苷在制备治疗和/或预防非酒精性脂肪肝病产品中的应用 |
| WO2021146247A1 (en) | 2020-01-13 | 2021-07-22 | The Feinstein Institutes For Medical Research | Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen |
| US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| WO2022245878A1 (en) | 2021-05-17 | 2022-11-24 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| KR20250039366A (ko) * | 2022-06-17 | 2025-03-20 | 코다젠 바이오사이언시스 인코포레이티드 | 시르투인 활성화 화합물을 포함하는 시르투인 조절 화합물, 및 이의 응용 |
| US12012370B1 (en) | 2022-12-29 | 2024-06-18 | Codagen Biosciences, Inc. | Sirtuin modulating compounds and applications thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1108698B (de) | 1959-09-03 | 1961-06-15 | Hoechst Ag | Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen |
| US3517007A (en) * | 1968-04-05 | 1970-06-23 | American Home Prod | 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds |
| ZA735753B (en) | 1972-09-14 | 1974-07-31 | American Cyanamid Co | Resolution of 6-substituted amino phenyl-2,3,5,6-tetrahydro(2,1-b)thiadiazoles |
| US4018932A (en) * | 1975-11-03 | 1977-04-19 | American Cyanamid Company | Anthelmintic pour-on formulations for topical use on domestic and farm animals |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4939133A (en) * | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
| JPH0576084A (ja) | 1991-09-11 | 1993-03-26 | Matsushita Electric Ind Co Ltd | 遠隔表示装置 |
| JPH05289689A (ja) | 1992-04-06 | 1993-11-05 | Sanyo Electric Co Ltd | 可搬性規則音声合成装置 |
| JPH07291976A (ja) | 1994-04-27 | 1995-11-07 | Otsuka Pharmaceut Factory Inc | イミダゾ〔２，１−ｂ〕チアゾール誘導体 |
| US6653309B1 (en) * | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| CA2450555A1 (en) * | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| KR20040031782A (ko) | 2001-07-27 | 2004-04-13 | 쿠리스 인코퍼레이션 | 헤지호그 신호전달 경로의 조절물질, 이를 함유하는조성물 및 이의 용도 |
| HUP0103987A3 (en) | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
| HUP0103986A2 (hu) | 2001-09-28 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| JP2005298333A (ja) | 2001-11-15 | 2005-10-27 | Meiji Seika Kaisha Ltd | 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤 |
| CA2517720A1 (en) * | 2003-03-11 | 2004-09-23 | Pfizer Products Inc. | Pyrazine compounds as transforming growth factor (tgf) inhibitors |
| WO2004080481A1 (en) | 2003-03-13 | 2004-09-23 | Novo Nordisk A/S | Novel nph insulin preparations |
| ATE464286T1 (de) | 2003-12-15 | 2010-04-15 | Japan Tobacco Inc | Cyclopropanderivate und ihre pharmazeutische verwendung |
| US7714161B2 (en) | 2004-01-20 | 2010-05-11 | Brigham Young University | Sirtuin activating compounds and methods for making the same |
| BRPI0510074A (pt) * | 2004-04-22 | 2007-10-16 | Boehringer Ingelheim Int | composições farmacêuticas para o tratamento de distúrbios sexuais ii |
| US7776326B2 (en) * | 2004-06-04 | 2010-08-17 | Washington University | Methods and compositions for treating neuropathies |
| EP1819341A4 (en) | 2004-11-10 | 2011-06-29 | Synta Pharmaceuticals Corp | IL-12 MODULATORY CONNECTIONS |
| CA2599989A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| UA92746C2 (en) | 2005-05-09 | 2010-12-10 | Акилайон Фармасьютикалз, Инк. | Thiazole compounds and methods of use |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| CA2617557A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| AU2008221263B2 (en) | 2007-03-01 | 2012-02-23 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| CL2008001821A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| CA2705138A1 (en) | 2007-11-08 | 2009-05-14 | Sirtris Pharmaceuticals, Inc. | Solubilized thiazolopyridines |
| US20100168084A1 (en) * | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
-
2008
- 2008-06-19 CL CL2008001821A patent/CL2008001821A1/es unknown
- 2008-06-19 TW TW097122811A patent/TW200918542A/zh unknown
- 2008-06-20 NZ NZ581989A patent/NZ581989A/en not_active IP Right Cessation
- 2008-06-20 ES ES08768696.0T patent/ES2534544T3/es active Active
- 2008-06-20 AU AU2008266746A patent/AU2008266746B2/en not_active Ceased
- 2008-06-20 BR BRPI0813653-0A2A patent/BRPI0813653A2/pt not_active Application Discontinuation
- 2008-06-20 UY UY31170A patent/UY31170A1/es not_active Application Discontinuation
- 2008-06-20 EP EP08768696.0A patent/EP2167510B1/en active Active
- 2008-06-20 AR ARP080102662A patent/AR067106A1/es unknown
- 2008-06-20 MX MX2009013976A patent/MX2009013976A/es active IP Right Grant
- 2008-06-20 JP JP2010513266A patent/JP5281081B2/ja not_active Expired - Fee Related
- 2008-06-20 US US12/214,804 patent/US7829556B2/en not_active Expired - Fee Related
- 2008-06-20 MY MYPI20095422A patent/MY149316A/en unknown
- 2008-06-20 UA UAA201000211A patent/UA104127C2/ru unknown
- 2008-06-20 KR KR1020107000398A patent/KR101525268B1/ko not_active Expired - Fee Related
- 2008-06-20 PE PE2008001057A patent/PE20090423A1/es active IP Right Grant
- 2008-06-20 WO PCT/US2008/007771 patent/WO2008156866A1/en not_active Ceased
- 2008-06-20 CN CN2008801034489A patent/CN101874031B/zh not_active Expired - Fee Related
- 2008-06-20 EA EA201070034A patent/EA018182B1/ru not_active IP Right Cessation
- 2008-06-20 CA CA2692099A patent/CA2692099C/en not_active Expired - Fee Related
-
2009
- 2009-12-11 DO DO2009000283A patent/DOP2009000283A/es unknown
- 2009-12-14 ZA ZA200908882A patent/ZA200908882B/xx unknown
- 2009-12-14 IL IL202729A patent/IL202729A/en not_active IP Right Cessation
-
2010
- 2010-01-08 CO CO10001888A patent/CO6261382A2/es active IP Right Grant
- 2010-01-15 MA MA32518A patent/MA31568B1/fr unknown
- 2010-01-20 CR CR11231A patent/CR11231A/es unknown
- 2010-09-27 US US12/891,667 patent/US8247565B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530431A5 (cg-RX-API-DMAC10.html) | ||
| JP2010530432A5 (cg-RX-API-DMAC10.html) | ||
| RU2445312C2 (ru) | ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR | |
| US20040209891A1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | |
| JP2012512907A5 (cg-RX-API-DMAC10.html) | ||
| RU2559888C2 (ru) | Аналоги этомидата, которые не ингибируют синтез адренокортикостероидов | |
| AU2002244860A1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | |
| JP2011502958A5 (cg-RX-API-DMAC10.html) | ||
| JP2011500545A5 (cg-RX-API-DMAC10.html) | ||
| JP2004528334A5 (cg-RX-API-DMAC10.html) | ||
| WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
| JP2007519649A5 (cg-RX-API-DMAC10.html) | ||
| JP2005002129A5 (cg-RX-API-DMAC10.html) | ||
| JP2005526696A5 (cg-RX-API-DMAC10.html) | ||
| JP2008503533A5 (cg-RX-API-DMAC10.html) | ||
| MA28706B1 (fr) | Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques | |
| JP2007530493A5 (cg-RX-API-DMAC10.html) | ||
| JP2011524896A5 (cg-RX-API-DMAC10.html) | ||
| JP2012515788A5 (cg-RX-API-DMAC10.html) | ||
| JP2013518036A5 (cg-RX-API-DMAC10.html) | ||
| WO2006085113A3 (en) | 2-substituted 5-membered heteroaryl carboxylates as hm74a receptor agonists | |
| NO20034007D0 (no) | N-fenylarylsulfonamidforbindelse, legemiddel inneholdende forbindelsen somaktiv bestanddel, mellomprodukt for forbindelsen, ogfremgangsmåter for fremstilling av samme | |
| NO20064811L (no) | 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase | |
| RU2003131970A (ru) | Производные 4-(фенил-пиперидин-4-илиден-метил)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств | |
| EA019037B1 (ru) | 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1 |